Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by barmac6on Feb 04, 2011 1:27pm
263 Views
Post# 18076952

dailybuyselladviser

dailybuyselladviser

Hotter than climate change

Contarians these investors may be, but that doesn’t mean they turn away from popular sectors. Thus they “continue to navigate the fertile fields of the agricultural sector.”

The President’s Portfolio in Contra the Heard contains Hemisphere GPS (TSX-HEM), which has been “hotter than climate change.” Early in January the stock shot up to $1.57. It has since settled down to $1.45. It does not pay a dividend.

As its name suggests, the company supplies Global Navigation Satellite Systems (GNSS). Farm vehicles and machinery are not its only market, however. It also supplies systems to the oil and gas, marine and aerospace industries.

It has lost money steadily, thanks largely to its Research and Development costs, point out the Contra Guys. “Maybe more focused spending is in order,” they reflect.

On the other hand, it pulled in record third-quarter revenue and the balance sheet is “squeaky clean.” As farm revenue keeps going up, so should this stock, the contrarians reckon.

“Insiders appear confident, pumping in money, apparently believing that a turnaround is in store, and perhaps sooner rather than later.”

A takeover is certainly a welcome bonus for any investor, but when you’re piling up double-digit returns, you can always wait ‘til next year.


https://www.dailybuyselladviser.com/news/blank/turnaround-stocks1160-1.html

Bullboard Posts